Voorhees, P., Dimopoulos, M., Cohen, Y., Schjesvold, F., Hungria, V., Sandhu, I., Lindsay, J., Baker, R., Suzuki, K., Kosugi, H., Levin, M., Beksac, M., Stockerl-Goldstein, K., Magen, H., Oriol, A., Mikala, G., Garate, G., Theunissen, K., Špička, I., Mylin, A., Hallam, S., Bringhen, S., Uttervall, K., Pula, B., Khan, A., Medvedova, E., Ye, J. C., Cowan, A., Moreau, P., Mateos, M., Goldschmidt, H., Vieyra, D., Raval, A., Sha, L., Li, L., Rousseau, E., Dennis, R., Carson, R., Rajkumar, S. V. (2025). Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age. Blood. https://doi.org/10.1182/blood-2025-372